ライフサイエンスコーパス: rheumatic

1 on between periodontal infection markers and rheumatic activity.

2 EGylated TRAIL (TRAILPEG) is profoundly anti-rheumatic against two complementary experimental RA mous

3 ), which is a gold-containing classical anti-rheumatic agent and a PKCiota-specific inhibitor, result

4 anofin, a drug initially approved as an anti-rheumatic agent, which also possesses potent antibacteri

5 Several diseases, including inflammatory rheumatic and autoimmune diseases, infections, and malig

6 igen (HLA) genes known to be associated with rheumatic and infectious diseases and complement C4 gene

7 The management of rheumatic and musculoskeletal diseases has transformed o

8 l strategies for arterial revascularization, rheumatic and other valvular heart disease, and symptoma

9 , peripheral artery disease, cancer, liver-, rheumatic-, and chronic kidney disease (CKD).

10 y with the risk of subsequent development of rheumatic autoimmune diseases in women, including rheuma

11 stemic lupus erythematosus, thyroiditis, and rheumatic autoimmune diseases.

12 introduce new treatments to individuals with rheumatic autoimmune inflammatory diseases (RAIDs), ofte

13 ed attention on the role of B lymphocytes in rheumatic autoimmune/inflammatory diseases (RAIDs), but

14 ow concentrations of PLP are associated with rheumatic, cardiovascular, and neoplastic diseases.

15 ocarditis; however, in the developing world, rheumatic carditis, Trypanosoma cruzi, and bacterial inf

16 d as a central pathogenic factor in multiple rheumatic conditions and has been shown to act via a wid

17 with systemic lupus erythematosus and other rheumatic conditions, there may still be reluctance to i

18 ic bacteriuria (AB) in women with autoimmune rheumatic disease (ARD) are scarce.

19 lales abundance are implicated in arthritis, rheumatic disease and diabetes.

20 iscussed, along with their putative roles in rheumatic disease and therapeutic options for targeting

21 t drugs used in other specialties may induce rheumatic disease and vigilance on making a diagnosis is

22 ch exhibit differential association with the rheumatic disease ankylosing spondylitis (AS).

23 Scleroderma is a chronic autoimmune rheumatic disease associated with widespread tissue fibr

24 siological mechanisms of musculoskeletal and rheumatic disease caused by SINV are inadequately unders

25 S: New genetic associations in patients with rheumatic disease have been reported for disease modifyi

26 literature related to the risk of autoimmune rheumatic disease in association with pregnancy history.

27 (PMR) is the second most common inflammatory rheumatic disease of the elderly after rheumatoid arthri

28 e risk of developing inflammatory autoimmune rheumatic disease over a lifetime.

29 s available, showcases important advances in rheumatic disease research already powered by these tech

30 t the full potential of their application to rheumatic disease research has yet to be fulfilled.

31 omplaints, which can present as a definitive rheumatic disease such as calcium pyrophosphate dihydrat

32 Patients with the autoimmune rheumatic disease systemic lupus erythematosus (SLE) hav

33 irus (CHIKV) infection causes a debilitating rheumatic disease that can persist for months to years,

34 so called scleroderma, is an immune-mediated rheumatic disease that is characterised by fibrosis of t

35 roup 2 and, within group 1, in patients with rheumatic disease versus nonrheumatic cases.

36 all lifetime risk of inflammatory autoimmune rheumatic disease was 8.4% for women and 5.1% for men.

37 The trial was done in patients without rheumatic disease who tolerated LD-MTX during an active

38 rised 12 patients with IBD, 17 patients with rheumatic disease, and 19 healthy individuals (controls)

39 described as an autoantigen in patients with rheumatic disease, and Ro60 orthologs have been identifi

40 in unaffected cases, independent of maternal rheumatic disease, season at highest risk of cardiac NL

41 patients with AF with mitral disease and no rheumatic disease, the percentage of fibrosis and the fi

42 mediated diseases (diabetes mellitus type 1, rheumatic disease, thyroid disease, vitiligo, alopecia a

43 icrobiota in patients with IBD, but not with rheumatic disease, toward that of controls.

44 Macrophage activation syndrome is the rheumatic disease-associated member of a group of hyperi

45 adults secondary to infection, lymphoma, or rheumatic disease.

46 ed with adverse birth outcomes in women with rheumatic disease.

47 e adverse metabolic features associated with rheumatic disease.

48 se phenotype in a mouse model of RRV-induced rheumatic disease.

49 pediatric MAS varies based on the underlying rheumatic disease.

50 e in both adults and children diagnosed with rheumatic disease.

51 estimated the sex-specific lifetime risk of rheumatic disease.

52 hat has widely been used in the treatment of rheumatic disease.

53 ble Chikungunya-related chronic inflammatory rheumatic diseases (>3 month symptom duration from the i

54 5.5% vs. 0.1%), pancreatic (1.7% vs. 0%) and rheumatic diseases (7.2% vs. 1.2%; all P < 0.01).

55 se (RR 2.2 [1.6-2.9]), connective tissue and rheumatic diseases (RR 1.5 [1.3-1.7]), peripheral vascul

56 btained from our population-based studies of rheumatic diseases among residents of Olmsted County, Mi

57 ecificity in relation to patients with other rheumatic diseases and healthy controls was >90%.

58 SLE patients compared to patients with other rheumatic diseases and healthy subjects.

59 Patients with inflammatory rheumatic diseases and periodontitis share common pathog

60 m remains a promising therapeutic target for rheumatic diseases and requires further study.

61 on DNA methylation alterations in autoimmune rheumatic diseases and the advantages and disadvantages

62 ulated molecular mechanisms in patients with rheumatic diseases and the discovery of new therapeutic

63 marizes the effects pregnancy has on various rheumatic diseases and the effects these diseases have o

64 isks of malignancy associated with pediatric rheumatic diseases and their treatments are needed.

65 Autoimmune rheumatic diseases are genetically complex entities that

66 As most of the rheumatic diseases are multisystem, it is worthwhile exa

67 ystem dysfunction is common in children with rheumatic diseases complicated by MAS, and more organ sy

68 table proportion of individuals with chronic rheumatic diseases continue to be treated with these dru

69 The management of inflammatory rheumatic diseases during pregnancy and breastfeeding ha

70 of Chikungunya-related chronic inflammatory rheumatic diseases had not been reported so far.

71 Although the management of patients with rheumatic diseases has evolved substantially over the pa

72 underlying the pathogenenesis of autoimmune rheumatic diseases has led to targeted biological treatm

73 Rheumatic diseases have complex aetiologies that are not

74 intracellular targets of glucocorticoids in rheumatic diseases have not been fully identified.

75 ging typical for the most commonly diagnosed rheumatic diseases in children, such as juvenile idiopat

76 Differential diagnosis of rheumatic diseases is performed on the basis of localiza

77 e diagnostics and treatment of patients with rheumatic diseases of the musculoskeletal system, includ

78 the potential to severely affect those with rheumatic diseases or who are taking immunosuppressive t

79 mes and other clinical aspects in autoimmune rheumatic diseases reinforce the usefulness of DNA methy

80 Tracking many rheumatic diseases requires frequent monitoring of patie

81 nsive cells in both the bona fide autoimmune rheumatic diseases rheumatoid arthritis and systemic lup

82 tic glucocorticoids have been widely used in rheumatic diseases since they became available over 60 y

83 concepts in the management of patients with rheumatic diseases specifically, these concepts have bee

84 st that metals may have a role in triggering rheumatic diseases such as AS and also have implications

85 n fibrosis is a lethal outcome of autoimmune rheumatic diseases such as systemic sclerosis.

86 A and TST in a large cohort of patients with rheumatic diseases suggest that the IGRA provides greate

87 The spondyloarthropathies are a group of rheumatic diseases that are associated with inflammation

88 t four groups of drugs to potentially induce rheumatic diseases were anti-tumour necrosis factor (TNF

89 nt IFN pathways active in tissues of complex rheumatic diseases will be critical to classify disease,

90 is the most commonly used drug for systemic rheumatic diseases worldwide and is the recommended firs

91 d (210 SLE patients, 178 patients with other rheumatic diseases, and 205 healthy subjects).

92 are key pathogenic derangements in systemic rheumatic diseases, and these insights are leading to ch

93 ptive immune system like multiple sclerosis, rheumatic diseases, and type 1 diabetes.

94 er its role in multifaceted diseases such as rheumatic diseases, as well as other autoimmune and infl

95 Ultrasound cannot identify specific rheumatic diseases, but it does allow for an evaluation

96 portant mediator of cartilage destruction in rheumatic diseases, but our understanding of the upstrea

97 tional biomarkers and therapeutic targets in rheumatic diseases, but the full potential of their appl

98 sing results in preclinical animal models of rheumatic diseases, human clinical trials have, in gener

99 Spondyloarthropathies belong to a group of rheumatic diseases, in which inflammatory changes affect

100 Finally, rheumatic diseases, including rheumatoid arthritis and s

101 RA, as well as other inflammatory autoimmune rheumatic diseases, including systemic lupus erythematos

102 trasound is used in the initial diagnosis of rheumatic diseases, monitoring of the effectiveness of t

103 y associated with underlying hematologic and rheumatic diseases, respectively.

104 d substantial improvements in the control of rheumatic diseases, resulting in more patients with seve

105 nnovative therapeutic approaches for various rheumatic diseases, such as rheumatoid arthritis, juveni

106 and within inflamed tissue of patients with rheumatic diseases, such as rheumatoid arthritis, system

107 eutrophils in the pathogenesis of autoimmune rheumatic diseases, such as systemic lupus erythematosus

108 In many rheumatic diseases, the severity of the condition can re

109 As with many rheumatic diseases, there is growing interest in using g

110 ing mysteries in the pathogenesis of several rheumatic diseases, to identify new therapeutic targets

111 In today's modern day treatment of rheumatic diseases, ultrasonography and magnetic resonan

112 In rheumatic diseases, when immune responses are dysregulat

113 es in the biological treatment of autoimmune rheumatic diseases, with a particular focus on systemic

114 therapeutic strategies for many inflammatory rheumatic diseases.

115 inant Fc fusion protein widely used to treat rheumatic diseases.

116 ows one of the highest mortality rates among rheumatic diseases.

117 lidates uPA as a novel therapeutic target in rheumatic diseases.

118 udied areas include the muscles, tendons and rheumatic diseases.

119 , chronic obstructive pulmonary disease, and rheumatic diseases.

120 pregnancy and the future risk of autoimmune rheumatic diseases.

121 are critical to the pathogenesis of systemic rheumatic diseases.

122 been tested as therapeutics for inflammatory rheumatic diseases.

123 pregnancy-related research in patients with rheumatic diseases.

124 e of this biologic is now expanding to other rheumatic diseases.

125 ntal role in the diagnosis and monitoring of rheumatic diseases.

126 ertinent to the pathogenesis or treatment of rheumatic diseases.

127 h are defective, but correctable, in several rheumatic diseases.

128 elopment of inflammatory diseases, including rheumatic diseases.

129 l syndromes that closely mimic other primary rheumatic diseases.

130 nized for noninfectious association with the rheumatic diseases.

131 ty for SLE and 87% specificity against other rheumatic diseases.

132 be difficult to distinguish from idiopathic rheumatic diseases.

133 , including systemic lupus erythematosus and rheumatic diseases.

134 gnify new associations between drugs and the rheumatic diseases.

135 esses and challenges and with an emphasis on rheumatic diseases.

136 ions of personalized, targeted therapies for rheumatic diseases.

137 doption of telemedicine in the management of rheumatic diseases.

138 a potentially fatal complication of chronic rheumatic diseases.

139 and chronic inflammatory conditions such as rheumatic diseases.

140 e approach to the diagnosis and treatment of rheumatic diseases.

141 of autoimmune diseases, including autoimmune rheumatic diseases.

142 ich are central to the pathogenesis of these rheumatic diseases.

143 g MIF-related genetic susceptibility to many rheumatic diseases.

144 t insights into the complicated aetiology of rheumatic diseases.

145 for the treatment of a variety of autoimmune rheumatic diseases.

146 r pathways that underpin the pathogenesis of rheumatic diseases.

147 hway might in fact have clinical benefits in rheumatic diseases.

148 Scleroderma is an autoimmune rheumatic disorder accompanied by severe fibrosis in ski

149 esents similarly to reactive, neoplastic, or rheumatic disorders.

150 rference with B cell counts and functions in rheumatic disorders.

151 t possible temperature variations in various rheumatic disorders.

152 also determined after disease-modifying anti-rheumatic drug (DMARD) treatment in the inflammatory art

153 vity, compound T-614 (also known as the anti-rheumatic drug iguratimod), and found that, in addition

154 response to synthetic disease modifying anti-rheumatic drugs (DMARDs) from 35 rheumatology department

155 ression with biologic disease-modifying anti-rheumatic drugs (DMARDs), such as tumour necrosis factor

156 ed treatment with any disease-modifying anti-rheumatic drugs, were enrolled from eight secondary care

157 CR) results, face psychosocial disorders and rheumatic, ear-nose-throat, neurocognitive, and ophthalm

158 ation of illness, Disease Activity Score 28, rheumatic factor [RF], anti-cyclic citrullinated peptide

159 atient-years), 19 (0.6%) had recurrent acute rheumatic fever (3.49/1000 patient-years), and 20 (0.7%)

160 Although acute rheumatic fever (ARF) and its sequel, rheumatic heart di

161 gated adverse outcomes for people with acute rheumatic fever (ARF) and rheumatic heart disease (RHD)

162 Both rheumatic fever (cases) and tuberculosis (controls) were

163 The authors compared the prevalence of rheumatic fever among the relatives of 33 children admit

164 tives of 33 children admitted for "incident" rheumatic fever and 33 control children admitted in a tu

165 iated with serious sequelae, including acute rheumatic fever and acute glomerulonephritis.

166 he current hypotheses of the pathogenesis of rheumatic fever and group A streptococcal autoimmune seq

167 rategies for the primary prevention of acute rheumatic fever and rheumatic heart disease in children

168 Acute rheumatic fever and rheumatic heart disease remain major

169 Acute rheumatic fever and subsequent rheumatic heart disease r

170 presence of an "inherited predisposition" to rheumatic fever because the disease was more prevalent a

171 tional guidelines for the diagnosis of acute rheumatic fever by defining high-risk populations, recog

172 The incidence of acute rheumatic fever declined from 6.1 to 3.7 cases/100,000 (

173 storic Jones criteria used to diagnose acute rheumatic fever in the context of the current epidemiolo

174 icant knowledge gaps in the understanding of rheumatic fever pathogenesis and suggest that a GAS vacc

175 of population-specific differences in acute rheumatic fever presentation and changes in presentation

176 t of GAS pharyngitis are cornerstones of the Rheumatic Fever Prevention Programme, but these are hind

177 Acute rheumatic fever remains a serious healthcare concern for

178 of New Zealand where the incidence of acute rheumatic fever remains unacceptably high.

179 -specific antibody responses associated with rheumatic fever were identified from 1 January 1944 to 3

180 e revised Jones criteria were used to define rheumatic fever with a maximum period of 4 weeks between

181 d aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in

182 r transient ischemic attack, recurrent acute rheumatic fever, and infective endocarditis.

183 fections, myringotomy, measles, hepatitis A, rheumatic fever, common colds, rubella and chronic sinus

184 Cardiovascular Disease in the Young and its Rheumatic Fever, Endocarditis, and Kawasaki Disease Comm

185 ation under the auspices of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Cou

186 ans to diagnose cardiac involvement in acute rheumatic fever, even when overt clinical findings are n

187 We included 411 cases of rheumatic fever, for which microbiological characterizat

188 l on the hereditary versus social origins of rheumatic fever, Read, Ciocco, and Taussig, from Johns H

189 Once primarily caused by rheumatic fever, the most common pathogenesis today is a

190 othesis is proven in a few illnesses such as rheumatic fever, there is no definitive evidence of an i

191 ted motifs were present in only 15.1% of the rheumatic fever-associated emm types and only 24.8% of c

192 Rheumatic fever-associated emm types were disseminated t

193 med to provide a comprehensive list of acute rheumatic fever-associated GAS isolates and assess the p

194 Rheumatic fever-associated motifs were present in only 1

195 was used to analyze the protein diversity of rheumatic fever-associated strains in a phylogenetic tre

196 skin infection and pharyngitis-induced acute rheumatic fever.

197 a tuberculosis clinic for reasons other than rheumatic fever.

198 f carditis as a major manifestation of acute rheumatic fever.

199 sses and 2 (0.28%) were diagnosed with acute rheumatic fever.

200 tries with the added factors of SH, C'D, and rheumatic fever.

201 logic manifestation of streptococcal-induced rheumatic fever.

202 ly with a decrease in the incidence of acute rheumatic fever.

203 lementation of evidence-based strategies for rheumatic fever/RHD prevention, (3) access to essential

204 art disease were older than children without rheumatic heart disease (median age [interquartile range

205 Rheumatic heart disease (RHD) affects ~40 million people

206 Rheumatic heart disease (RHD) after group A streptococcu

207 people with acute rheumatic fever (ARF) and rheumatic heart disease (RHD) and the effect of comorbid

208 emporaneous estimate of the global burden of rheumatic heart disease (RHD) from echocardiographic pop

209 Rheumatic heart disease (RHD) is a complication of group

210 Rheumatic heart disease (RHD) is a leading cause of prem

211 Echocardiographic screening for rheumatic heart disease (RHD) is becoming more widesprea

212 Rheumatic heart disease (RHD) remains a major public hea

213 High-risk patients with rheumatic heart disease (RHD) who were undergoing valve

214 Rheumatic heart disease (RHD), an autoinflammatory heart

215 acute rheumatic fever (ARF) and its sequel, rheumatic heart disease (RHD), continue to cause a large

216 he South Pacific experience a high burden of rheumatic heart disease (RHD).

217 ntially powerful tool for early diagnosis of rheumatic heart disease (RHD).

218 hest prevalence rates of clinically detected rheumatic heart disease (RHD).

219 nt gold standard for the diagnosis of latent rheumatic heart disease (RHD).

220 Rheumatic heart disease according to the World Heart Fed

221 Rheumatic heart disease affects 1 in 100 schoolchildren

222 rval, 29.7 million to 43.1 million) cases of rheumatic heart disease and 10.5 million (95% uncertaint

223 re is no vaccine to prevent diseases such as rheumatic heart disease and invasive streptococcal infec

224 ive autoantibodies which target the valve in rheumatic heart disease and the neuronal cell in Sydenha

225 countries, including the cardiac effects of rheumatic heart disease and the vascular effects of mala

226 arly detection and the treatment of clinical rheumatic heart disease are required to improve outcomes

227 ds in the prevalence of and mortality due to rheumatic heart disease as part of the 2015 Global Burde

228 health of women with unoperated and operated rheumatic heart disease before, during, and after pregna

229 and years of life lost (YLL) as measures of rheumatic heart disease burden using the GBD Results Too

230 The global burden of rheumatic heart disease continues to be significant alth

231 Global age-standardized mortality due to rheumatic heart disease decreased by 47.8% (95% uncertai

232 ncer due to hepatitis B virus (9.4 million), rheumatic heart disease due to streptococcal infection (

233 atically reviewed data on fatal and nonfatal rheumatic heart disease for the period from 1990 through

234 ort the 2-year follow-up of individuals with rheumatic heart disease from 14 low- and middle-income c

235 llion) disability-adjusted life-years due to rheumatic heart disease globally.

236 n which a companion document on advocacy for rheumatic heart disease has been developed.

237 Although rheumatic heart disease has been nearly eradicated in hi

238 The health-related burden of rheumatic heart disease has declined worldwide, but high

239 Patients with clinical rheumatic heart disease have high mortality and morbidit

240 an monoclonal antibodies (mAbs) derived from rheumatic heart disease have provided evidence for cross

241 interval, 297,300 to 337,300) deaths due to rheumatic heart disease in 2015.

242 mary prevention of acute rheumatic fever and rheumatic heart disease in children presenting with phar

243 regional burden, trends, and inequalities of rheumatic heart disease in the Americas.

244 We analysed 1990-2017 trends in rheumatic heart disease mortality and prevalence, quanti

245 ality, and classified countries according to rheumatic heart disease mortality in 2017 and 1990-2017.

246 22%) had both the highest level of premature rheumatic heart disease mortality in 2017 and the smalle

247 We showed that in 2017 rheumatic heart disease mortality in the Americas was 51

248 A significant reduction in rheumatic heart disease mortality occurred, from a regio

249 ce, quantified cross-country inequalities in rheumatic heart disease mortality, and classified countr

250 GBD 2017 estimated that 3 604 800 cases of rheumatic heart disease occurred overall in the Americas

251 e current management strategies for valvular rheumatic heart disease on the basis of either strong ev

252 pared with other primary presentations) were rheumatic heart disease or congestive cardiac failure, c

253 the mortality and morbidity associated with rheumatic heart disease or information on their predicto

254 surface antigens may lead to valve damage in rheumatic heart disease or neuropsychiatric behaviors an

255 l disease prevalence of and mortality due to rheumatic heart disease over a 25-year period.

256 Acute rheumatic fever and rheumatic heart disease remain major global health probl

257 Acute rheumatic fever and subsequent rheumatic heart disease remain significant in developing

258 Rheumatic heart disease remains an important preventable

259 e greatly reduced premature mortality due to rheumatic heart disease since 1990.

260 Countries with less favourable rheumatic heart disease situations should be targeted fo

261 one transitions in developed countries, from rheumatic heart disease to a degenerative calcific patho

262 ealth Assembly 2018 approved a resolution on rheumatic heart disease to strengthen programmes in coun

263 The prevalence of borderline or definite rheumatic heart disease was 10.2 (95% CI, 7.5-13.0) per

264 ndardized mortality due to and prevalence of rheumatic heart disease were observed in Oceania, South

265 Children with rheumatic heart disease were older than children without

266 se, nonischemic and Chagas cardiomyopathies, rheumatic heart disease, and congenital heart anomalies,

267 ion, aortic and peripheral arterial disease, rheumatic heart disease, and endocarditis.

268 prevalent pretransition forms of HF such as rheumatic heart disease, and underdevelopment of healthc

269 iomyopathy, atrial fibrillation and flutter, rheumatic heart disease, aortic aneurysm, peripheral art

270 ent of patients with atrial fibrillation and rheumatic heart disease, for the treatment of patients w

271 ally associated with intravenous drug abuse, rheumatic heart disease, prosthetic heart valves, pacema

272 predominantly communicable diseases such as rheumatic heart disease, tuberculous pericarditis, or ca

273 including cardiac surgery for congenital and rheumatic heart disease.

274 sorders, including schistosomiasis, HIV, and rheumatic heart disease.

275 he best opportunity to address the burden of rheumatic heart disease.

276 nd its peptides appear during progression of rheumatic heart disease.

277 ange of life-threatening diseases, including rheumatic heart disease.

278 T cells in peripheral blood and in rheumatic heart valves revealed the presence of T cells

279 The presence of rheumatic, hepatobiliary, pancreatic, and dermatologic d

280 ising new tool for uncovering and monitoring rheumatic inflammation in vivo.

281 cytokines and are abundantly present in the rheumatic joint, induce proinflammatory cytokine express

282 ecules that trigger complement activation in rheumatic joints.

283 Rheumatic manifestations are the most frequent extra-int

284 le, clinicians should be familiar with these rheumatic manifestations in order to avoid misdiagnosis

285 Rheumatic manifestations may often be the initial presen

286 As for rheumatic manifestations, namely IBD-related arthritis,

287 ve repair is preferable over replacement for rheumatic mitral regurgitation but is not available to t

288 human atrial tissues from the patients with rheumatic mitral valve disease in either sinus rhythm or

289 ch other to promote the development of AF in rheumatic mitral valve disease.

290 A total of 128 patients with rheumatic MS without other significant valve disease wer

291 MS was categorized as rheumatic (n=170, 33%), postsurgical (prior mitral repai

292 ell types valuable for clinical treatment of rheumatic pathologies.

293 combinations of immunosuppressive therapy in rheumatic patients.

294 osphate dihydrate deposition disease or as a rheumatic symptom such as diffuse arthralgia.

295 e of causing a severe and often debilitating rheumatic syndrome in humans.

296 thogenic link between the malignancy and the rheumatic syndrome, the association between these diseas

297 Although paraneoplastic rheumatic syndromes are rare, clinicians should be aware

298 gs are continuously being developed and some rheumatic syndromes have been associated with specific d

299 PURPOSE OF REVIEW: To describe rheumatic syndromes that can be a paraneoplastic manifes

300 VIEW: Cocaine use is associated with several rheumatic syndromes.

301 lvular surgery, hypertrophic cardiomyopathy, rheumatic valvular disease, or greater than mild mitral